Findings

What do systematic reviews say?

1,497 questions · 1,590 findings · 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certainty Download CSV

No studies found 281 · 17.7%GRADE not reported 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%

Intervention not reported

Survival · ovarian carcinoma

1 finding from 1 review

Antigen‐specific active immunotherapy for ovarian cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1882 participants
High

Intervention not reported

Antigen‐specific immunogenicity (humoral response) · ovarian carcinoma

1 finding from 1 review

Antigen‐specific active immunotherapy for ovarian cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
25 studies · 1521 participants
Very low

Intervention not reported

Antigen‐specific immunogenicity (cellular response) · ovarian carcinoma

1 finding from 1 review

Antigen‐specific active immunotherapy for ovarian cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
40 studies · 966 participants
Very low

EGFR tyrosine kinase inhibitor (TKI) vs observation

Overall survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

EGFR tyrosine kinase inhibitor (TKI) showed no clear difference in overall survival compared with observation alone (low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 0.99 [0.81, 1.2]
1 study · 835 participants
Low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Quality of life: not measured · treatment of relapsed epithelial ovarian cancer

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Overall survival · treatment of relapsed epithelial ovarian cancer

Anti‐EGFR antibody plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 0.93 [0.74, 1.18]
4 studies · 658 participants
Moderate

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Progression‐free survival · treatment of relapsed epithelial ovarian cancer

Anti‐EGFR antibody plus chemotherapy showed no clear difference in progression‐free survival compared with chemotherapy alone (low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 0.9 [0.7, 1.16]
4 studies · 658 participants
Low

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Anaemia (grade ≥ 3) · treatment of relapsed epithelial ovarian cancer

Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 to 4 anaemia compared with chemotherapy alone (low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 0.84 [0.47, 1.49]
4 studies · 652 participants
Low

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Grade 3 to 4 diarrhoea · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea compared with chemotherapy alone (very low certainty).

2 findings from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 2.87 [0.59, 13.89]
4 studies · 652 participants
Very low
Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 6.37 [1.89, 21.45]
3 studies · 432 participants
Low

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Grade ≥ 3 diarrhoea · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea ‐ seribantumab compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 0.38 [0.07, 2.23]
1 study · 220 participants
Very low

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Toxicity: grade 3 or 4 nausea ± vomiting · treatment of relapsed epithelial ovarian cancer

Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 1.27 [0.56, 2.89]
3 studies · 503 participants
Low

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Toxicity: grade 3 or 4 fatigue · treatment of relapsed epithelial ovarian cancer

Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 fatigue compared with chemotherapy alone (low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 1.06 [0.66, 1.73]
4 studies · 652 participants
Low

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Toxicity: grade 3 or 4 hypokalaemia · treatment of relapsed epithelial ovarian cancer

Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 hypokalaemia compared with chemotherapy alone (low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 2.01 [0.8, 5.06]
3 studies · 522 participants
Low

EGFR tyrosine kinase inhibitor (TKI) vs observation

Progression‐free survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) changes progression‐free survival compared with observation alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 1.05 [0.9, 1.23]
1 study · 835 participants
Very low

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Quality of life · treatment of relapsed epithelial ovarian cancer

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

EGFR tyrosine kinase inhibitor (TKI) vs observation

Quality of life · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 835 participants
Very low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Overall survival · treatment of relapsed epithelial ovarian cancer

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 1.25 [0.8, 1.95]
1 study · 129 participants
Low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Progression‐free survival · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes progression‐free survival compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 0.99 [0.69, 1.42]
1 study · 129 participants
Very low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Grade 3 to 4 rash · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 rash compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 13.63 [0.78, 236.87]
1 study · 125 participants
Very low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Toxicity: grade 3 or 4 nausea ± vomiting · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 0.63 [0.16, 2.52]
1 study · 125 participants
Very low